A breast cancer-selective oncolytic adenovirus was engineered to express antagonists of vascular endothelial growth factor (VEGF) and Notch signaling to combine direct anticancer activity with disruption of tumor-associated angiogenesis. Replication of the parental virus, AdEHE2F, is stimulated by estrogen receptor (ER), E2F1 and hypoxia, and it mediates selective lysis of breast cancer cells in vitro and in vivo. Here, we encoded soluble Flt-1 (sFlt1) and soluble Dll4 (sDll4) under control of the E3 promoter. sFlt1 (the extra-cellular domain of VEGF receptor 1) binds VEGF-A and inhibits stimulation of VEGFR2, decreasing angiogenic stimulus. Conversely, sDll4 (the extracellular domain of Delta-like 4) antagonizes Notch signaling to prevent endothelial maturation. We hypothesized that these agents might show additive or synergistic activity. In vitro, sFlt1 inhibited endothelial cell proliferation and sprouting, whereas sDll4 increased the number of vascular branchpoints. In ER-positive ZR75.1 tumors in vivo AdEHE2F showed the potent direct virotherapy with no augmentation owing to sFlt1 or sDll4; however, in ER-negative MDA-231 tumors efficacy was enhanced by encoding sFlt1 or sDll4, with survival time extending to double that of controls. There was also a dramatic decrease in the total number of tumour blood vessels, as well as the number of perfused vessels, suggesting that improved efficacy reflects combined anti-tumour and anti-vascular effects.
INTRODUCTION
Tumor development depends on a complex interaction of many different cell types, including non-transformed cells that are employed by the tumor to fulfill supporting functions. Tumor growth and the emergence of invasive and metastatic cancers are crucially dependent on recruitment of vascular endothelium to provide blood supply, which can nourish the solid tumor mass. Several angiogenic factors have a role in promoting tumor vascularization, notably fibroblast growth factor (FGF2) and vascular endothelial growth factor (VEGF), and several recent 'angiotherapy' innovations target emerging or established vasculature as the accessible Achilles' heel of cancer biology [1] [2] [3] [4] These agents provide a complementary approach to conventional cancer therapy, although they can cause significant side effects such as rashes, lethargy, hypertension and occasional serious visual cortex problems. 5 Virotherapy provides a new approach to cancer therapy, [6] [7] [8] where lytic viruses are engineered to replicate selectively within tumor cells and lyse them, before spreading to infect adjacent cells. Such conditionally replicating 'oncolytic' viruses exploit tumor-associated changes and are generally unable to replicate in non-transformed cells such as tumor-associated endothelial cells, although several authors have reported strategies to improve anticancer activity by arming them with therapeutic transgenes. 9 Genes encoding cytotoxic proteins such as prodrug-activating thymidine kinase and cytosine deaminase, 10, 11 proapoptotic proteins such as TNF-a (Tumor Necrosis Factor alpha) 12 or immunostimulatory proteins such as GM-CSF 13 or IL-24 14 have been encoded within oncolytic adenoviruses, and it is clearly possible to consider encoding anti-vascular or anti-angiogenic proteins in the same way. [15] [16] [17] [18] This approach could combine maximum concentrations of 'angiotherapy' within tumors (where it is needed) while minimizing systemic toxicities.
To assess whether virotherapy can be usefully combined with angiotherapy, we decided to encode the first three extracellular domains (sFlt1) of VEGF receptor 1 and soluble Delta-like 4 (sDll4, containing the nine extracellular domains of human Dll4) within oncolytic adenoviruses. sFlt1 exerts its anti-angiogenic activity by sequestering and neutralizing tumor-secreted VEGF, 19 whereas sDll4 antagonizes activation of endothelial Notch signaling 20 by Jagged-1 and inhibits vascular maturation, 21, 22 causing chaotic and nonfunctional angiogenesis in several tumor models. 20, 23, 24 Interestingly, VEGF-A and Dll4 are haploinsufficient for normal fetal development, and are recognized as central factors in tumor angiogenesis. 20, 23, [25] [26] [27] With a view to treating breast cancer, we previously compared several oncolytic group C adenoviruses in vitro and in vivo for their potency and cancer selectivity. 28 The optimum agent was identified as AdEHE2F, 29 a type 5 adenovirus where the E1A promoter was replaced by binding sites for the estrogen receptor (ER) and hypoxia-inducible factor (HIF1a/HIF2a), while transcription of E4 is driven by the E2F1 promoter. AdEHE2F was thus designed to replicate in cells with elevated HIF (increased in hypoxia and a constitutive hallmark of many breast cancer cells 30 ) or active estrogenic signaling (found in B80% of all breast cancer cases 31 ), and it was used as a platform in the present study to express sFlt1 and sDll4. Here, we compared the activities of AdEHE2F expressing either sFlt1 (AdEHE2F-sFlt1) or sDll4 (AdEHE2F-sDll4) in vitro and in vivo, and assess whether these agents can augment the efficacy of AdEHE2F virotherapy in treating human breast cancer in vivo.
MATERIALS AND METHODS
Cloning a fragment of sFlt1 and sDll4 into AdEHE2F
A non-replicating adenovirus coding for full-length soluble sFlt1 (6 extracellular domains) was provided by Professor Ronald Crystal (Weill Medical College of Cornell University, USA) 32 and used as a DNA template to clone the first three extracellular domains (nucleotides 237-1263, NM_002019) using the following primers: 5 0 -GCC TCG AGA ATC GAT AGC GCT CAC CAT GGT CAG CTA CT-3 0 and 5 0 -GCC AAG CTT ATC GAT TTA ATG TTT CAC AGT GAT GAA TGC-3 0 . For amplification of the extracellular domain of human Dll4 (nucleotides 321-1901 NM_019074), the following primers were used: 5 0 -TAT TCG AAA GCC ACC ATG GCG GCA GCG TCC CGG AGC GCC T-3 0 and 5 0 -GAT TCG AAT TAG AAG CTG GGC GGC AAG CCC ACG-3 0 . Amplified sFlt1 and sDll4 were cloned using the TOPO TA cloning system (Invitrogen, Paisley, Scotland) and inserted into the AdEasy System (QBiogene, Montreal, Quebec, Canada) or AdEHE2F. Detailed protocol can be requested. Table 1 shows the summary of the characteristics of viruses used in this study.
Proliferation assay HUVEC (500 cells/well in a 96-well plate) were grown in the presence of increasing amounts of conditioned supernatant from MDA-231 cells infected with AdEHE2F-sFlt1, AdEHE2F-sDll4 or AdEHE2F-Luc (considered as 100% survival) viruses in EGM-2 media at 100 MOI for 30 h. MTS assay (Promega, Southampton, UK) was performed after 4 (for AdEHE2F-sFlt1) or 6 days (for AdEHE2F-sDll4) of addition of conditioned media.
Bead assay
The bead assay was described previously. 33 Conditioned media containing sFlt1 or sDll4 expressed from AdEHE2F-X was added to the bead assay and replaced every other day for 12 days.
Western blot
Antibodies used were anti-VEGFR1 at 1:500 dilution (V4262, Sigma, Poole, UK), anti-Dll4 at 1:500 (ab7280, AbCam, Cambridge, UK), HRP anti-mouse at 1:1000 dilution (A9917, Sigma).
In vivo studies MDA-231 cells were injected subcutaneously (2 Â 10 6 cells) in the flank of 4-6-week-old MF1 nude female mice (Harlan). In the ZR75.1 tumor model, estradiol pellets (0.72 mg of 17b-estradiol, 90 day release; Innovative Research of America) were injected subcutaneously with a trochar in the neck of MF1 nude mice. Three days later 2 Â 10 6 ZR75.1 cells were injected subcutaneously. Adenoviruses were injected intratumorally when tumors were B100 mm 3 (MDA-231) or 200 mm 3 (ZR75.1). For efficacy studies, mice received two sets of injections (2 Â 10 9 vp/tumor in two injections of 40 ml, each for three consecutive days in week 1 and 2), giving a total dose of 1.2 Â 10 10 vp. The treatment groups received either virotherapy alone (AdEHE2F-Luc, two sets of injections) or combination therapy AdEHE2F-sFlt1 (two sets of injections), AdEHE2F-sDll4 (two sets of injections), AdEHE2F-sFlt1 then AdEHE2F-sDll4 (one set of injections of each, in either order) and AdEHE2F-sFlt1 þ AdEHE2F-sDll4 (two sets of injections containing both viruses at 1 Â 10 9 vp each). Control tumors were injected (two sets of injections) with E1, E3-deleted non-replicating AdLuc. In the MDA-231 tumor model, the angiotherapy groups were also included, with non-replicating adenovirus expressing sFlt1 (AdsFlt1, two sets of injections) or sDll4 (AdsDll4, two sets of injections). Tumors were measured three times per week using the formula: Tumor volume ¼ (length Â width Â depth) Â (p/6). 34 For vessel studies in MDA-231, tumors were injected using the same protocol as in efficacy study and analyzed after 13-17 days post first injection; in the ZR75.1 model, tumors were injected four times with 10 ml each on day 1 with a total of 1.2 Â 10 10 viral particles and tumors were collected at day 7 and 14.
Immunohistochemistry
Anti-adenovirus at 1:500 (MAB805, Chemicon, Watford, UK) was used for virus detection. To detect hypoxia, 30 min before killing, mice were injected intraperitoneally with a 1.5-mg hypoxiprobe (Chemicon), and an anti-hypoxiprobe-FITC antibody (1:200 dilution) was used subsequently. In the MDA-231 model, frozen sections were used and an anti-CD31 antibody (BM4086, Acris) was used at 1:100. For perfused vessels staining, mice were injected i.v. with biotinylated lycopersicon esculentum lectin (100 mg/ mouse, Vector Labs) for 3 min before killing. Images were captured using a Nikon eclipse 80i microscope and NIS-Elements Monochrome camera software at Â 10 or Â 20 magnification. The number of vessels and percentage of area of vessels per field was quantified by the microscope images (1024 pixels x 1344 pixels; in tif format) using a custom-made program written in MatLab (version 7.2, The MathWorks, Cambridge, UK).
In vitro and in vivo luciferase assays
In vitro, cells were infected with 100 vp/cell of adenovirus. At defined times, potassium luciferin (158 mg/ml in PBS) solution was added and luciferase activity was measured using a Wallac Victor 2 1420 multilabel counter. For in vivo studies, mice were injected intraperitoneally with 100 ml potassium luciferin (15.8 mg/ml in PBS), and images were acquired 4 min later using the IVIS camera (Xenogen, Cambridge, UK).
Statistical analysis
Luciferase expression was analyzed by one-way analysis of variance (ANOVA) using Prism 4 software (GraphPad, San Diego, CA, USA) with Bonferroni correction for multiple analyses. Number of branches in bead assay, perfused and all vessel number data were analyzed by ANOVA single factor using Excel software (Microsoft, Redmond, WA, USA). Analysis of covariance adjusting for initial tumor size was used to analyze daily tumor growth (ER-positive) and log of daily growth rate (ER-negative) in SAS (SAS Institute, Cary, NC, USA). Survival is the time from first treatment injection until sacrifice due to maximum tumor size (10% of animal's weight) or ulceration. Survival was calculated using the Kaplan-Meier method, and log-rank tests were performed for comparisons with more than five expected events per group.
RESULTS

Selectivity of AdEHE2F-X transgene expression
The oncolytic adenovirus AdEHE2F shows increased replication in ER-positive cancer cells and/or under hypoxic conditions, 28, 29 providing a good candidate for virotherapy of breast cancer. In this study, the virus was modified by replacing E3 6.7 K/gp19K with open reading frames encoding luciferase (AdEHE2F-Luc), sFlt1 (AdEHE2F-sFlt1) or sDll4 (AdEHE2F-sDll4) (referred to collectively as AdEHE2F-X), maintaining E3 promoter, splicing and polyadenylation control over transgene expression ( Figure 1a ). AdEHE2F-Luc was produced as a 'virotherapy alone' control for direct comparison with AdEHE2F-sFlt1 and AdEHE2F-sDll4; however it also allows evaluation of the effects of cellular conditions on E1A expression, as increased E1A levels should transactivate the E3 promoter leading to increased luciferase levels as well as promoting virus replication. In ER-positive ZR75.1 cells, AdEHE2F-luc showed 10-fold greater luciferase expression in the presence of estrogen (2.5 nM) than in the absence, 19-fold increased expression in hypoxia (1% O 2 for 16 h) and 30-fold greater expression when estrogen and hypoxia were combined Combination of virotherapy and angiotherapy M Bazan-Peregrino et al ( Figure 1b ). In ER-negative MDA-231 cells exposure to hypoxia led to 18-fold more luciferase expression than controls after 30 h, whereas estrogen had no effect. Infection and replication of AdEHE2F-luc were also assessed in vivo, monitoring luciferase activity in tumors and sites of potential toxicity. To discern virus replication, the underlying pattern of infection alone was shown using E1, E3-deletedAdLuc, which has an identical viral capsid structure but contains luciferase under the control of the CMV promoter. Following direct intratumoral injection into ER-negative MDA-231 xenografts, AdLuc showed approximately equal luciferase expression in the tumor and liver (Figure 1c ), consistent with 'overflow' of virus from the tumor into the circulation as we have shown previously. 35 In contrast, IT injection of AdEHE2F-Luc showed high luciferase expression in the tumor (consistent with increased E1A activity reflecting virus replication) and no detectable hepatic expression. This suggests that AdEHE2F-luc undergoes tumor-restricted replication and transgene expression as intended in its molecular design, 28, 29 with little or no replication in most normal tissues. Using an ER-positive ZR75.1 xenograft, which is known to be less prone to overflow following IT injection, 35 both AdLuc and AdEHE2F-Luc showed similarly high levels of luciferase expression in tumors, coupled with no hepatic expression. These data demonstrate the efficient activation of E1A expression by AdEHE2F within two different breast cancer xenografts, suggesting it may be active across a range of breast cancer types.
Immunohistochemical analysis of AdEHE2F-X replication in vivo The ability of AdEHE2F to replicate selectively in tumors, including ER-negative tumors, may be influenced by the activation of HREs. To determine whether AdEHE2F-Luc replicates preferentially within hypoxic areas of ER-negative tumors, dual immunohistochemical staining was performed for adenovirus using an antihexon antibody (red staining, Figure 2 ) and hypoxia using an anti-hypoxiprobe antibody (green staining). In both ER-negative MDA-231 and ER-positive ZR75.1 tumors there was a strong colocalization (highlighted with arrows) of the hypoxiprobe (green) with the adenovirus hexon (red). Whereas detectable adenovirus was largely restricted to areas of hypoxia in ER-negative MDA-231 tumors, the pattern of adenovirus staining was far more widespread and intense in ER-positive ZR75.1 tumors with virus found in both hypoxic and normoxic regions. This difference 10 viral particles of AdEHE2F-Luc. After 13-17 days tumors were analyzed by double staining immunohistochemistry to detect adenovirus (red) and hypoxia (green), slides were counterstained with DAPI to stain nuclei (blue). Arrows show areas that were stained for both hypoxia and virus and arrow heads show areas stained for virus, but no hypoxia.
suggests that hypoxia is the sole trigger for virus replication in ERnegative MDA-231 tumors, but that replication in the ER-positive ZR75.1 model can be facilitated by an ER-dependent mechanism even in the absence of hypoxia (Figure 1b and Figure 2 ).
Expression of angiogenic regulatory proteins from AdEHE2F-X The production of sFlt1 and sDll4 by MDA-231 cells infected with AdEHE2F-sFlt1 and AdEHE2F-sDll4 was confirmed by western blotting of 'conditioned' media (Figure 3a) . Functionality was shown by assessing angiogenesis-modulating effects using an endothelial cell proliferation assay and a 3D tubulogenesis assay 33 ( Figure 3 ). Conditioned medium containing sFlt1 expressed from AdEHE2F-sFlt1 showed dose-dependent inhibition of proliferation (up to 50%) of subconfluent endothelial cells (Figure 3b ). In contrast, high doses of AdEHE2F-sDll4-conditioned medium increased proliferation of endothelial cells (Figure 3b) , with viability reaching 120% of controls. This is similar to the effect reported for antagonism of Notch in endothelial cells, thought to reflect uncoordinated endothelial proliferation. 36 The effects of sFlt1 and sDll4 on angiogenesis were further tested using a 3D fibrin gel assay, which allows vessel growth and morphology to be assessed in vitro. Whereas conditioned medium from cells infected with AdEHE2F-sFlt1 completely inhibited endothelial sprouting, conditioned medium from cells infected with AdEHE2F-sDll4 instigated normal sprouting and twofold more secondary branches at the vessel tip (Figures 3c and d) , similar to the improved secondary branching reported when Notch activity is blocked in vivo.
37-39
Effects of AdEHE2F-X viruses on the growth of an ER-positive tumor model In the ER-positive ZR75.1 model, the anticancer efficacy of single agent virotherapy (using AdEHE2F-Luc) was compared with combination therapies using AdEHE2F expressing sFlt1 or sDll4, either singly or together (see Materials and Methods). The total virus dose was 1.2 Â 10 10 particles in each case, given through intratumoral injection. Control tumors (injected with non-replicating AdLuc) grew rapidly and required the median animals to be put down due to tumor burden after 31 days (Figure 4a ). In contrast, virotherapy alone (AdEHE2F-luc) and virotherapy combined with sFlt1 and/or sDll4 (AdEHE2F-sFlt1, AdEHE2F-sDll4, individually or applied together at half doses) inhibited tumor growth by a daily average of 42 mm 3 (95% CI 25 to 59, Po0.0001) compared with controls. Some individual tumors showed regression following treatment with AdEHE2F-sFlt1 or AdEHE2F-sDll4, a response not observed with parental AdEHE2F-Luc; however, virotherapy mediated by AdEHE2F-Luc inhibited overall tumor growth so successfully that the average tumor growth rate was not further inhibited using AdEHE2F-sFlt1 or AdEHE2F-sDll4 (P ¼ 0.21). There was also no significant difference in tumor growth between combination therapies using one or both of AdEHE2F-sFlt1 and AdEHE2F-sD114 (P ¼ 0.69), again reflecting the potency of all these therapeutic approaches against these ERpositive tumors (Figure 4a ).
Effects of AdEHE2F-X viruses on growth of an ER-negative tumor model
We assessed whether potentiation by angiotherapy treatments might be easier to discern in a more aggressive model such as the ER-negative human breast cancer MDA-231. Estrogen independence of this tumor suggests that HIF will be the main tumorassociated factor promoting E1A expression and thereby replication. In this model, we found that non-replicating adenoviruses expressing sFlt1 or sDll4 (see Materials and Methods) did not show any inhibition of tumor growth compared with the AdLuc control group (P ¼ 0.80, dark green line in Figure 4b) . Similarly, virotherapy with AdEHE2F-Luc achieved no significant growth inhibition compared with controls (P ¼ 0.49, red line), demonstrating the difficulty of treating this model successfully. However, combined virotherapy and angiotherapy, using AdEHE2F encoding either sFlt1 or sDll4 (purple line), or a mixture of AdEHE2F-sFlt1 and AdEHE2F-sDll4 (each applied at half doses; light green line) resulted in a significant delay in tumor growth, giving an average reduction in tumor growth rate by 5.4% compared with the use of non-replicating adenoviruses expressing sFlt1 or sDll4 (95% confidence interval (CI) 2.9-7.9% reduction, P ¼ 0.0001). Combination therapy was also better than virotherapy alone, showing a 3.5% reduction (95% CI 0.1-6.8% reduction) in mean growth rate (P ¼ 0.04).
It has been reported that blockade of Notch signaling increases VEGFR2 and decreases VEGFR1 levels in endothelial cells, 21 thereby making angiogenesis more responsive to VEGF. To test whether the order of applying anti-angiogenic treatments would affect their overall anticancer activity, AdEHE2F-sDll4 was given during the first week (to maximize dependence of tumor angiogenesis on VEGF) and then AdEHE2F-sFlt1 during the second week (and vice versa). However, there was no evidence for an advantage of using one injection of each angiogenic agent compared with two injections of the same agent (P ¼ 0.73). To simplify graphical representation, data from groups receiving both angiotherapies were grouped into 'Virotherapy þ 2 Angiotherapy' in Figure 4b . (Figure 4c ). It can be seen that survival is not extended by angiogenic therapy alone or virotherapy alone; however, combination therapy using either sFlt1 or sDll4 with virotherapy (that is, AdEHE2F-sFlt or AdEHE2F-sDll4, purple line) increased median survival by B50% (38 days, 95% CI 25-49) compared with angiotherapy alone (25 days, 95% CI 14-38). Similarly, combination therapy using both angiotherapies with virotherapy (that is, AdEHE2F-sFlt and AdEHE2F-sDll4, light green line) almost doubled the median survival time (45 days, 95% CI 32-52) compared with the control group (23 days, 95% CI inestimable, as n ¼ only 5) (Figure 4c) . A similar pattern of survival outcomes was seen in the data from the ZR75.1 model, although the differences were smaller and did not make significance (data not shown).
Effect of AdEHE2F-X viruses on MDA-231 tumor vasculature To define the mechanisms underlying the increased survival seen when anti-angiogenic agents were combined with virotherapy, we characterized the effects of AdEHE2F-sFlt1 and AdEHE2F-sDll4 viruses on the vasculature of MDA-231 tumors. A representative section taken at 7 days is shown in Figure 5a where vasculature is shown in red, well-perfused vessels are in green and adenovirus is in white. It can be seen that only a proportion of total vessels are actively perfused at any time, and both the total vasculature and perfused vasculature appeared decreased by angiotherapy treatment. Virus replication can also be seen (white signal), although as expected it is some distance from perfused vasculature, perhaps reflecting the effects of hypoxia. The relative numbers of vessels per field were quantified under blinded conditions and treatment with combination therapy of AdEHE2F-sFlt1 þ AdEHE2F-sDll4 was shown to significantly decrease the total vessel number (36-55% 
DISCUSSION
The central hypothesis driving this study was that a combination of virotherapy with genetically encoded anti-angiogenic therapy would provide greater anticancer activity than virotherapy alone, and that agents antagonizing VEGF and Notch signaling might provide additive or synergistic anti-angiogenic activity in this context. We addressed this by inserting two highly potent regulators of angiogenesis; sFlt1 (antagonizes VEGF-A activity) or sDll4 (antagonizes Notch activation) 20, 23 into a breast cancer-selective oncolytic adenovirus (AdEHE2F). 28, 29 Both sFlt1 and sDll4 have been previously shown to exert a good therapeutic effect in tumor models, 20, 23, 32 emphasizing their suitability for this role.
Transgenes can be inserted into oncolytic adenoviruses either under independent transcriptional control using mammalian or viral promoters 16 or their transcription can be made dependent on virus replication. The latter is often achieved by placing the transgene under control of the E3 promoter 40 or major late promoter. 11 In this study, both strategies were compared and it was observed that the presence of the CMV promoter in the E3 region (to drive the independent transcription of sFlt1) made the AdEHE2F vector unstable, with only low levels of transgene expression in vitro and very little activity in vivo (data not shown). The suggestion that endogenous E3 regulatory signals are preferable to the introduction of exogenous CMV promoter in this region accords with the findings of Hawkins and Hermiston. 41 Therapeutic transgene expression regulated by the E3 promoter within AdEHE2F was successfully contained within the tumor for both tumor models studied, despite likely transfer of virus into the systemic circulation (Figure 1c ). This is important as unwanted transgene expression can lead to harmful toxicity, for example, hemorrhage from overexpression of sFlt1 in the mouse liver. 42 Lack of hepatic luciferase expression from AdEHE2F-Luc in this study suggests that there would be negligible toxicity in the liver from AdEHE2F-sFlt1 for either tumor model. Efficient tumorselective expression most likely reflects hypoxic conditions in both tumor types and estrogenic conditions in the ZR75.1 tumoractivating expression of E1A, a key factor for viral replication and activation of the E3 promoter.
This interpretation of the factors regulating virus replication was supported by immunohistochemical analysis for adenovirus hexon, showing AdEHE2F-X replication mainly in hypoxic areas in ER-negative MDA-231 tumor and at both hypoxic and nonhypoxic sites of ER-positive ZR75.1 tumor (Figure 2 ). The selectivity observed in vivo reflects that characterized in vitro, where activation of ERE and HRE within the E1A promoter of AdEHE2F increased E3 transgene expression 29-fold (Figure 1b) , most likely a combination of E3 promoter induction and genome replication.
To enhance the antitumoral activity of AdEHE2F we encoded sFlt1, one of the most powerful known regulatory angiogenic agents, which acts by antagonizing the VEGF-A signaling pathway. 43, 44 However, as tumors often exhibit redundancy in their angiogenic pathways (and might resist antagonism of VEGF alone), we also aimed to inhibit the Notch pathway by expressing sDll4 to promote dysfunctional angiogenesis. 45, 46 These mediators showed their expected activities in vitro, with conditioned medium containing sFlt1 demonstrating strong inhibition of endothelial proliferation and sprouting (Figures 3b and c) , whereas conditioned medium containing Dll4 mediated the opposite effects (Figures 3b and d) .
In addition, neither sDll4 nor sFlt1 affected the tumour cell growth of MDA-231 and ZR75.1 cells in vitro (data not shown), thereby suggesting that any enhancement in antitumoral efficacy given by sFlt1 or sDll4 expressed from AdEHE2F would come from their activity on endothelial cells and not on cancer cells directly.
In the ER-positive ZR75.1 model, there was no evidence for improved anticancer activity when angiotherapy was combined with virotherapy, although the potency of virotherapy alone in this model meant that improvements would have been hard to discern (Figure 4a ). ER-negative MDA-231 tumors provide a more stringent test bed for treatment with AdEHE2F-X agents, with virotherapy alone showing no significant ability to decrease tumor growth rate and no enhancement of median survival compared with controls. Angiotherapy alone, using sFlt1 and sDll4 expressed from non-replicating viruses also showed no therapeutic effect. However, when virotherapy and angiotherapy were combined, there was a significant decrease in tumor growth rate coupled with a significant increase in median survival time (Figures 4b  and c ). This effect was seen for virotherapy combined with sFlt1, sDll4 either singly or combined, although there was no evidence for improved activity of the combination. Analysis of tumor vasculature in animals receiving both virotherapy and angiotherapy (compared with virotherapy alone) suggested that decreased levels of total blood vessels and perfused blood vessels may well have contributed to the improved anticancer activity seen.
Although we observed that the sequential use of AdEHE2F-sDll4 followed by AdEHE2F-sFlt1 (or vice versa) was not more effective than AdEHE2F-sDll4 alone or AdEHE2F-sFlt1 alone in both tumor models, the variety of responses to therapies targeting VEGF and Dll4 reported in the literature 20, 23, 24, 47 suggest that further investigation of this point in different breast cancer models may be warranted.
Finally, we investigated the effect of virally expressed sDll4 and sFlt1 on the vasculature near sites of virus replication in ZR75.1 tumors. Contrary to expectation, treatment with AdEHE2F-sDll4 alone did not show an increase in (supposed dysfunctional) vessel number, whereas treatment with AdEHE2F-sFlt1 did give a lower microvascular density near sites of viral infection (data not shown). We speculate that sFlt1 may be a more effective angiogenic modulator than sDll4 when expressed from a virus within a tumor, as sFlt1 can bind and neutralize its target, VEGF-A, as it moves through the interstitial matrix, whereas sDll4 acts directly on endothelial cells and must achieve active concentrations at sites of growing vasculature, potentially some distance from the site of protein synthesis. Intravenous use of Notch antagonists may achieve better vascular access, and thereby provide a more successful strategy to disrupt tumor vascular development. 20, 23 In this study, we have confirmed our central hypothesis that designing an oncolytic virus to mediate both anticancer and antiangiogenic activities leads to improved anticancer activity. Our data show that angiotherapy can be used to augment the therapeutic effect of virotherapy, giving significant disruption of tumor vasculature and at least additive inhibition of tumor growth. The strong selectivity of these viruses to replicate only within cancer cells suggests that side effects through aberrant transgene expression should be minimal, and these agents are strong candidates for preclinical and clinical development for treatment of breast cancer.
